Protease inhibitors as anticancer drugs: Role of molecular modelling and combinatorial chemistry in drug design

International Journal of Medicine, Biology and the Environment

Volumn 28, Issue 2, 2000, Pages 161-173

  Frecer, V ^a   Maliar, T ^a   Miertus, S ^a  

^a UNIDO   (Italy)

Author keywords

Anticancer drugs; Molecular modelling; Protease inhibitors; Tumor growth

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ANTINEOPLASTIC AGENT; ASPARTIC PROTEINASE; BATIMASTAT; BE 16627B; CAMOSTAT MESILATE; CATHEPSIN D; CATHEPSIN E; CGS 27023A; COLLAGENASE; CT 1418; CYSTATIN; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; GELATINASE; ILOMASTAT; MARIMASTAT; MATRILYSIN; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; PEPSTATIN; PRINOMASTAT; PROTEINASE INHIBITOR; REBIMASTAT; SERINE PROTEINASE; SOLIMASTAT; TANOMASTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE;

ARTICLE; BIOCHEMISTRY; BIOTECHNOLOGY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; COMPUTER AIDED DESIGN; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DESIGN; DRUG RESEARCH; HUMAN; LABORATORY; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR MODEL; TECHNIQUE; TUMOR CELL;

EID: 0034434735     PISSN: 1128935X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Cancer invasion and metastasis: Positive and negative regulatory elements
2. Protease inhibitors: Role and potential therapeutic use in human cancer
3. Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer
4. The role of the extracellular matrix in tumour invasion, metastasis and angiogenesis
5. Tumor-associated urokinase-type plasminogen activator: Biological and clinical significance
6. Cathepsin B and cystatin: Evidence for a role in cancer progression
7. Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer
8. Degradation of laminin by human tumor cathepsin B
9. Cathepsin-D in human breast cancer: Correlation with vascular invasion and other clinical and histopathological characteristics
10. The origin of matrix metalloproteinases and their familial relationships
11. A matrix metalloproteinase expressed on the surface of invasive tumour cells
12. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissues
13. Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: Relative prognostic value versus total cathepsin D
14. Tumor cell interactions with the extracellular matrix during invasion and metastasis
15. Localization of 92-kDa type IV collagenase in human skin tumors: Comparison with normal human fetal and adult skin
16. The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion
17. Comparative localization of receptors for plasmin and for urokinase on MCF7 cells
18. Tumour biology. Membrane proteases in focus
19. Urokinase-type plasminogen activator and its receptor: New targets for antimetastatic therapy?
20. The serpin superfamily of protease inhibitors: Structure, function, and regulation
21. Natural protein proteinase inhibitors and their interaction with proteinases
22. Structure and mechanism of action of serpins
23. Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design
24. The matrix metalloproteinases and their inhibitors
25. Characterization of the functional domain of tissue inhibitor of metalloproteinasses-2 (TIMP-2)
26. Structural analysis of tissue inhibitor of metalloproteinases-1 (TIMP-1) by tryptic peptide mapping
27. Thiol based inhibitors of mammalian collagenase. Substituted amide and peptide derivatives of the leucine analogue, 2-[(R Sm)-mercaptomethyl]-4-methylpentanoic acid
28. Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor
29. Protease inhibitors: Current status and future prospects
30. Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: Modification of the P1 and P2-residues
31. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
32. A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen
33. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
34. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
35. MMP inhibitors: Experimental and clinic studies
36. Clinical potential of matrix metalloprotease inhibitors in cancer therapy
37. Ongoing trials with matrix metalloproteinase inhibitors
38. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in patient-like orthotopic model in nude mice
39. A synthetic metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
40. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line
41. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2
42. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases
43. Overexpression of metalloproteinase inhibitor in B16-F10 cells does not affect extravasation but reduces tumor growth
44. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
45. Concepts of Combinatorial chemistry and combinatorial technologies
46. General method for rapid synthesis of multicomponent peptide mixtures
47. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator
48. (4-Aminomethyl) phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase